Abstracts tagged "Myositis"

Abstract Number: 1202 • ACR Convergence 2025
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Ka Ki Yam¹, Lucas Tsz Ho Luk¹, Weng Nga Lao², Chiu Wai Shirley Chan³, Dennis Tin Ho Chan⁴, Billy Tin Lok Lai⁵, Roy Tsz Chung Ho⁶, Vivian Hoi Shan Tang⁷, Ho So⁸ and Iris Tang⁹, ¹Department of Medicine & Geriatrics, Hong Kong, Hong Kong, ²Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, North District Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁹Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0291 • ACR Convergence 2025
Acute onset inflammatory myositis: Clinical features and survival.
Gollakota Nandita¹, Madhuri Challa², Phani Kumar D³, Meghna Gavali⁴ and Liza rajasekhar⁵, ¹NIMS, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³NIMS, Hyderabad, Telangana, India, ⁴nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, ⁵Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are characterized by subacute onset symmetric proximal muscle weakness, with occasional extra-muscular involvement, leading to significant morbidity and mortality. Acute…
Abstract Number: 2067 • ACR Convergence 2025
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Ilke Coskun Benlidayi¹, Meghna Lama², Oladipo Kunle Afolayan², Meera Shah³, Manali Sarkar⁴, Tamar Rubinstein⁵, Aleksandra Opinc-Rosiak⁶, Rada Miskovic⁷, Marcin Milchert⁸, Dimitri Luz Felipe da Silva⁹, Samuel Katsuyuki Shinjo¹⁰, Elena Nikiphorou¹¹, Ioannis Parodis¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Cukurova University, Adana, Turkey, ²The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, ³Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ⁴Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁵Albert Einstein College of Medicine, White Plains, NY, ⁶Medical University of Lodz, Zeromskiego ¹¹³, ⁹⁰-⁵⁴⁹ Lodz, Poland., Lodz, Poland, ⁷University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, ⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, ¹⁰Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹¹King's College London, London, United Kingdom, ¹²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Darya S. Jalaledin¹, Aidan pye², Angela Chang², Navid Saleh², Saud AlHajeri³, Beatrice Daviault⁴, Arusa Shah⁵, Sabrina Hoa⁶, Océane Landon-Cardinal⁷, Alec Yu², Robert Levy⁸, Jennifer Wilson⁹, Charles Poirier⁴, James Choi², John Yee², Hyein Kim² and Kun Huang¹⁰, ¹Université de Montréal, Saint-Lambert, QC, Canada, ²University of British Columbia, VANCOUVER, BC, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹UBC, Vancouver, BC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
Abstract Number: 0789 • ACR Convergence 2025
Short Form 36 (SF-36) Health Survey Questionnaire in Health-Related Quality of Life Assessment in Patients with Inflammatory Myopathies
Almurtada Razok¹, Jasmin Taylor², Ethan Ritz³, Kristin Wipfler⁴, Kaleb Michaud⁵ and Didem Saygin⁶, ¹John H Stroger Jr Hospital of Cook County, Chicago, IL, ²Rush Medical College, Chicago, IL, ³Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ⁴FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) experience significant impairment in their health-related quality of life (QoL); however, there are currently no validated measures to…
Abstract Number: 0289 • ACR Convergence 2025
Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Didem Saygin¹, Matthew Diller², Varsha Surampudi³, Mark Bodkin³, Payam Farhadi⁴, Adam Schiffenbauer⁵, Audrey Kessel³, Chris Mecoli⁶, Rohit Aggarwal⁷, Helene Alexanderson⁸, Michelle Best⁹, Olivier Benveniste¹⁰, Hector Chinoy¹¹, Brian Feldman¹², Linda Kobert¹³, Manuel Lubinus¹⁴, Liza McCann¹⁵, Chester V. Oddis¹⁶, Nicolino Ruperto¹⁷, Jens Schmidt¹⁸, Victoria Werth¹⁹, Christie Bartels²⁰, Hanna Kim²¹, Andrew Mammen²², Julie Paik²³, Ellen M. Werner¹³, Ingrid de Groot²⁴, Pedro Machado²⁵, Susan Kim²⁶, Tahseen Mozaffar²⁷, Adam M Huber²⁸, Angelo Ravelli²⁹, Richard Scheuermann² and Lisa Rider³⁰, ¹Rush University Medical Center, Chicago, IL, ²National Library of Medicine, National institutes of Health, Bethesda, MD, ³Social Scientific System Inc, a DLH holding company, Baltimore, MD, ⁴National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁵National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Cure JM Foundation, Lessburg, VA, ¹⁰Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Myositis Association, Columbia, MD, ¹⁴Myositis Support and Understanding, Lincoln, DE, ¹⁵Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ¹⁸Immanuel University Hospital Ruedersdorf, Brandenburg Medical School, Rudersdorf, Germany, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ²¹NIAMS, NIH, Bethesda, MD, ²²NIH, Bethesda, MD, ²³Johns Hopkins Rheumatology, Baltimore, MD, ²⁴The Myositis Association, Rotterdam, Netherlands, ²⁵University College London, London, United Kingdom, ²⁶UCSF Benioff Children's Hospital, San Francisco, CA, ²⁷University of California, Irvine, Orange, CA, ²⁸IWK Grace Health Centre, Halifax, NS, Canada, ²⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ³⁰National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Recent progress has been made in developing myositis outcome assessments, response and classification criteria, and consensus in the design and conduct of clinical trials…
Abstract Number: 2066 • ACR Convergence 2025
Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies
Meera Shah¹, Emilia Naseva², Tsvetelina Velikova³, Tamar Rubinstein⁴, Manali Sarkar⁵, Lavanya Mangla⁶, Oliver Distler⁷, Ingrid de Groot⁸, Lisa Christ⁹, Carlo Vinicio Caballero Uribe¹⁰, Ai Lyn Tan¹¹, Abraham Edgar Gracia Ramos¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ²Faculty of Public Health, Medical University of Sofia, ¹⁵ Acad. Ivan Evstratiev Geshov, ¹⁶⁰⁶ Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ³Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ⁴Albert Einstein College of Medicine, White Plains, NY, ⁵Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁶Maulana Azad Medical College, ²-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁸The Myositis Association, Rotterdam, Netherlands, ⁹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ¹⁰Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, ¹¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, ¹²Department of Internal Medicine, General Hospital, National Medical Center “La Raza”, Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. ⁰²⁹⁹⁰ Mexico City, Mexico., Mexico City, Mexico, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Traditional clinical measures are well established in idiopathic inflammatory myopathies (IIM), yet exploration of subjective well-being (SWB) remains limited. SWB assessment facilitates holistic patient…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 1198 • ACR Convergence 2025
Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
Christina Duesing¹, Ayla Nadja Stuetz², Andrea-Hermina Györfi³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Gamal Chehab⁶, Jutta Richter⁷, Marie Celine van Saan⁸, Bilgesu Safak Tümerdem², Alexandru-Emil Matei⁹, Bjoern Buehring¹⁰, Ricardo Grieshaber-Bouyer¹¹, Melanie Hagen¹², Georg Schett¹³, Wolfgang Merkt¹⁴ and Jörg Distler¹⁵, ¹Klinik für Rheumatologie, Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ⁷Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ⁸Department of Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich Heine University, Duesseldorf, ⁹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ¹⁰Bergisches Rheuma-Zentrum, Wuppertal, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine ³ - Rheumatology and Immunology, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁴University Hospital Düsseldorf, Düsseldorf, Germany, ¹⁵University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Treatment of anti-synthetase syndrome (ASyS) presents clinical challenges: myositis can lead to permanent disability and severe organ involvement is life-threatening.Methods: We treated three patients…
Abstract Number: 0357 • ACR Convergence 2025
Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)
Jason Xenakis¹, Esther Yi¹, Iyar Mazar², Sarah Knight³, Harriet Makin³, Samantha Wratten³, Rohit Aggarwal⁴ and Stephanie McKee³, ¹Pfizer Inc., New York, United States of America, New York, ²Pfizer, US, New York, ³Clarivate, London, United Kingdom, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
Abstract Number: 0288 • ACR Convergence 2025
Predictors and Characteristics of Objective Flares in Adult Dermatomyositis
Didem Saygin¹, York Wang², Kathryn C. Fitzgerald³, Jemima Albayda⁴, Julie Paik⁵, Eleni Tiniakou⁶, Brittany L Adler², Andrew Mammen⁷, Lisa Christopher-Stine⁴ and Chris Mecoli², ¹Rush University Medical Center, Chicago, IL, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶UT Health Science Houston, Houston, TX, ⁷NIH, Bethesda, MD
Background/Purpose: Dermatomyositis (DM) is a chronic systemic autoimmune disease with a heterogenous clinical course. Flares often lead to increased morbidity, health care utilization, and reduced…
Abstract Number: L06 • ACR Convergence 2024
Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies
Raphael Kirou¹, Iago Pinal-Fernandez¹ and Andrew Mammen², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD
Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
Abstract Number: L07 • ACR Convergence 2024
The Classification Criteria for Anti-Synthetase Syndrome (Class) Project
Giovanni Zanframundo¹, Sara Faghihi Kashani², Akira Yoshida³, Eduardo Dourado⁴, Iazsmin Bauer Ventura⁵, Daphne Rivero Gallegos⁶, Aravinthan Loganathan⁷, Gianluca Sambataro⁸, Francisca Bozan⁹, Sangmee Bae¹⁰, Darosa Lim¹¹, Marta Cheli¹², Yasuhiko Yamano¹³, Francesco Bonella¹⁴, Tamera Corte¹⁵, Tracy J. Doyle¹⁶, David Fiorentino¹⁷, Miguel Gonzalez-Gay¹⁸, Marie Hudson¹⁹, Masataka Kuwana²⁰, Ingrid Lundberg²¹, Andrew Mammen²², Neil McHugh²³, Frederick Miller²⁴, Carlomaurizio Montecucco¹, Chester Oddis²⁵, Jorge Rojas-Serrano⁶, Jens Schmidt²⁶, Carlo Alberto Scirè²⁷, Albert Selva-O'Callaghan²⁸, Victoria Werth¹¹, Davide Rozza²⁹, Monica Morosini³⁰, Sara Bozzini³⁰, Lorenzo Cavagna¹, Rohit Aggarwal²⁵ and the CLASS project investigators, ¹Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and University of California, San Francisco, CA, ³Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ⁴Unidade Local de Saùde da Regiao de Aveiro and Aveiro Rheumatology Research Centre, Aveiro, Portugal; Universidade de Lisboa, Lisboa, Portugal, ⁵University of Chicago, Chicago, IL, ⁶Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Mexico, ⁷Royal National Hospital for Rheumatic Diseases and University of Bath, UK; Arthritis Australia, Broadway, Glebe, NSW, Australia, ⁸University of Enna "Kore", Enna, Italy, ⁹Hospital Clinico Universidad de Chile, Santiago de Chile, Chile, ¹⁰UCLA, Los Angeles, CA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy, ¹³Tosei General Hospital, Aichi, Japan, ¹⁴University of Duisburg-Essen, Essen, Germany, ¹⁵Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia, ¹⁶Brigham and Women's Hospital, Boston, MA, ¹⁷Stanford University, Redwood City, CA, ¹⁸IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹⁹McGill University, Montreal, QC, Canada, ²⁰Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²¹Karolinska Institutet, Stockholm, Sweden, ²²NIH, Bethesda, MD, ²³University of Bath, Bath, United Kingdom, ²⁴NIH, NIEHS, Durham, NC, ²⁵University of Pittsburgh, Pittsburgh, PA, ²⁶University Medical Center Goettingen, Goettingen, Germany, ²⁷Univeristy of Milano Bicocca, Milan, Italy and IRCCS San Gerardo dei Tintori Foundation, Monza, Italy, ²⁸Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²⁹Italian Society for Rheumatology, Milano, Italy, ³⁰Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Italy
Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…

« Previous Page
1
…
4
5
6
7
8
…
34
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].